Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease

L-DOPA therapy in Parkinson’s disease (PD) is limited due to emerging L-DOPA-induced dyskinesia. Research has identified abnormal dopamine release from serotonergic (5-HT) terminals contributing to this dyskinesia. Selective serotonin reuptake inhibitors (SSRIs) or 5-HT receptor (5-HTr) agonists can...

Descripción completa

Detalles Bibliográficos
Autores principales: Altwal, Feras, Padovan-Neto, Fernando E., Ritger, Alexandra, Steiner, Heinz, West, Anthony R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510243/
https://www.ncbi.nlm.nih.gov/pubmed/34641332
http://dx.doi.org/10.3390/molecules26195790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510243/
https://www.ncbi.nlm.nih.gov/pubmed/34641332
http://dx.doi.org/10.3390/molecules26195790

Ejemplares similares